Literature DB >> 27714576

Comparison of the Adipose and Luminal Mammary Gland Compartment as Orthotopic Inoculation Sites in a 4T1-Based Immunocompetent Preclinical Model for Triple-Negative Breast Cancer.

Jonas Steenbrugge1,2, Koen Breyne3, Sofie Denies4, Melissa Dekimpe3,4, Kristel Demeyere3, Olivier De Wever5, Peter Vermeulen6, Steven Van Laere6, Niek N Sanders4, Evelyne Meyer3.   

Abstract

Breast tumorigenesis is classically studied in mice by inoculating tumor cells in the fat pad, the adipose compartment of the mammary gland. Alternatively, the mammary ducts, which constitute the luminal mammary gland compartment, also provide a suitable inoculation site to induce breast cancer in murine models. The microenvironments in these compartments influence tumor cell progression, yet this effect has not been investigated in an immunocompetent context. Here, we compared both mammary gland compartments as distinct inoculation sites, taking into account the immunological aspect by inoculating 4T1 tumor cells in immunocompetent mice. Following tumor cell inoculation in the adipose compartment of non-pretreated/naive, hormonally pretreated/naive and non-pretreated/lactating mice, the primary tumors developed similarly. However, a slower onset of primary tumor growth was found after inoculations in the luminal compartment of non-pretreated/lactating mice. Despite this difference in tumor development rate, metastasis to the liver and lungs was equally observed and was accompanied by lymphatic spreading of tumor cells and progressive splenomegaly with both inoculation types. Chitinase 3-like 1 (CHI3L1) and lipocalin 2 (LCN2) served as innovative biomarkers for disease progression showing increased levels in primary tumors and sera of the non-pretreated/lactating inoculation groups. A slower increase in circulating CHI3L1 but not LCN2 levels, was observed after inoculations in the luminal compartment which corroborated the slower tumor development at this inoculation site. Our results highlight the critical impact of different mammary gland compartments on tumor development in syngeneic murine models and support the use of novel tumor progression biomarkers in an immune-competent environment.

Entities:  

Keywords:  4T1 immunocompetent preclinical model; Adipose and luminal compartment; Chitinase 3-like 1; Lipocalin 2; Orthotopic inoculation; Triple-negative breast cancer

Mesh:

Substances:

Year:  2016        PMID: 27714576     DOI: 10.1007/s10911-016-9362-7

Source DB:  PubMed          Journal:  J Mammary Gland Biol Neoplasia        ISSN: 1083-3021            Impact factor:   2.673


  28 in total

Review 1.  Intra-mammary ductal transplantation: a tool to study premalignant progression.

Authors:  Daniel Medina; David G Edwards; Frances Kittrell; Sangjun Lee; D Craig Allred
Journal:  J Mammary Gland Biol Neoplasia       Date:  2012-06-12       Impact factor: 2.673

Review 2.  Paradoxical roles of the immune system during cancer development.

Authors:  Karin E de Visser; Alexandra Eichten; Lisa M Coussens
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

3.  Human primary ductal carcinoma in situ (DCIS) subtype-specific pathology is preserved in a mouse intraductal (MIND) xenograft model.

Authors:  Kelli Elizabeth Valdez; Fang Fan; William Smith; D Craig Allred; Daniel Medina; Fariba Behbod
Journal:  J Pathol       Date:  2011-09-26       Impact factor: 7.996

4.  Allergen induced pulmonary inflammation enhances mammary tumor growth and metastasis: Role of CHI3L1.

Authors:  Stephania Libreros; Ramon Garcia-Areas; Patricia Keating; Nathalia Gazaniga; Philip Robinson; Alison Humbles; Vijaya L Iragavarapu-Charyulu
Journal:  J Leukoc Biol       Date:  2015-03-12       Impact factor: 4.962

5.  Circulating levels of matrix metalloproteinase-9 (MMP-9), neutrophil gelatinase-associated lipocalin (NGAL) and their complex MMP-9/NGAL in breast cancer disease.

Authors:  Xeni Provatopoulou; Antonia Gounaris; Eleni Kalogera; Flora Zagouri; Ioannis Flessas; Evgenios Goussetis; Afroditi Nonni; Ioannis Papassotiriou; George Zografos
Journal:  BMC Cancer       Date:  2009-11-04       Impact factor: 4.430

6.  Lipocalin 2 is a novel regulator of angiogenesis in human breast cancer.

Authors:  Jiang Yang; Brendan McNeish; Catherine Butterfield; Marsha A Moses
Journal:  FASEB J       Date:  2012-09-14       Impact factor: 5.191

7.  Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer.

Authors:  Maret Bauer; Jens C Eickhoff; Michael N Gould; Christoph Mundhenke; Nicolai Maass; Andreas Friedl
Journal:  Breast Cancer Res Treat       Date:  2007-06-07       Impact factor: 4.872

8.  Myoepithelial cell differentiation markers in ductal carcinoma in situ progression.

Authors:  Tanya D Russell; Sonali Jindal; Samiat Agunbiade; Dexiang Gao; Megan Troxell; Virginia F Borges; Pepper Schedin
Journal:  Am J Pathol       Date:  2015-09-04       Impact factor: 4.307

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ.

Authors:  Fariba Behbod; Frances S Kittrell; Heather LaMarca; David Edwards; Sofia Kerbawy; Jessica C Heestand; Evelin Young; Purna Mukhopadhyay; Hung-Wen Yeh; D Craig Allred; Min Hu; Kornelia Polyak; Jeffrey M Rosen; Daniel Medina
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

View more
  6 in total

1.  Transparent reporting of experimental parameters in assays measuring phenotypic steps in metastasis.

Authors:  Robin Boiy; Jonas Steenbrugge; Jan Van Deun; An Hendrix; Evelyne Meyer; Olivier De Wever
Journal:  Clin Exp Metastasis       Date:  2018-10-28       Impact factor: 5.150

2.  Intraductal Adaptation of the 4T1 Mouse Model of Breast Cancer Reveals Effects of the Epithelial Microenvironment on Tumor Progression and Metastasis.

Authors:  Huda I Atiya; Anna Dvorkin-Gheva; John Hassell; Shrusti Patel; Rachel L Parker; Adam Hartstone-Rose; Johnie Hodge; Daping Fan; Ann F Ramsdell
Journal:  Anticancer Res       Date:  2019-05       Impact factor: 2.480

3.  Anti-inflammatory signaling by mammary tumor cells mediates prometastatic macrophage polarization in an innovative intraductal mouse model for triple-negative breast cancer.

Authors:  Jonas Steenbrugge; Koen Breyne; Kristel Demeyere; Olivier De Wever; Niek N Sanders; Wim Van Den Broeck; Cecile Colpaert; Peter Vermeulen; Steven Van Laere; Evelyne Meyer
Journal:  J Exp Clin Cancer Res       Date:  2018-08-15

4.  Comparative Profiling of Metastatic 4T1- vs. Non-metastatic Py230-Based Mammary Tumors in an Intraductal Model for Triple-Negative Breast Cancer.

Authors:  Jonas Steenbrugge; Niels Vander Elst; Kristel Demeyere; Olivier De Wever; Niek N Sanders; Wim Van Den Broeck; Luc Dirix; Steven Van Laere; Evelyne Meyer
Journal:  Front Immunol       Date:  2019-12-17       Impact factor: 7.561

5.  OMO-1 reduces progression and enhances cisplatin efficacy in a 4T1-based non-c-MET addicted intraductal mouse model for triple-negative breast cancer.

Authors:  Jonas Steenbrugge; Niels Vander Elst; Kristel Demeyere; Olivier De Wever; Niek N Sanders; Wim Van Den Broeck; Eric Ciamporcero; Timothy Perera; Evelyne Meyer
Journal:  NPJ Breast Cancer       Date:  2021-03-17

6.  One cisplatin dose provides durable stimulation of anti-tumor immunity and alleviates anti-PD-1 resistance in an intraductal model for triple-negative breast cancer.

Authors:  Jonas Steenbrugge; Julie Bellemans; Niels Vander Elst; Kristel Demeyere; Josephine De Vliegher; Timothy Perera; Olivier De Wever; Wim Van Den Broeck; Ward De Spiegelaere; Niek N Sanders; Evelyne Meyer
Journal:  Oncoimmunology       Date:  2022-07-22       Impact factor: 7.723

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.